Fig. 1. Cell viability assay in prostate cancer cell lines after docetaxel and TRAIL treatment. Cells are exposed for 24 hours, and cell viability is determined using the MTT assay (A, B). Flow cytometry analysis of DU 145 shows that a combination of docetaxel 2 nM and TRAIL 100 ng/mL increases the proportion of Annexin V(+)/PI(+) (C). The expressions of EZH2 and DR4 in prostate cancer cell lines are shown. A WB assay is performed with specific antibodies against EZH2, DR4, DR5, and β-actin (D). After docetaxel treatment for 24 hours, the EZH2 level is decreased and the DR4 level is increased in DU 145 cells (E). The cell viability test is performed with a combination of docetaxel and TRAIL with or without the DR4 antagonist antibody (F). DR4: death receptor 4, DR5: death receptor 5, EZH2: enhancer of zeste homolog 2, ns: not significant, PI: propidium iodide, TRAIL: tumor necrosis factor-related apoptosis-inducing ligand, WB: western blot. ^***p<0.001.